Brokerage Reports
|
Updated on 04 Nov 2025, 06:06 am
Reviewed By
Akshat Lakshkar | Whalesbook News Team
▶
Bernstein, a US brokerage, has initiated coverage on Indian companies Swiggy and Zomato (Eternal) with an 'Outperform' rating and set target prices of ₹570 for Swiggy and ₹390 for Zomato. They are seen as best positioned to capture value in India's fast-growing food delivery (FD) and quick commerce (QC) markets. A key growth driver is the affluent Indian segment ('Top-5 per cent Lifestyle Concierges') willing to pay for convenience, representing an $80 billion opportunity by FY2030. Expansion into dining out, events, and ticketing is expected. While QC is competitive, it's not a "winner-takes-all" market, with leaders like Blinkit, Instamart, and Zepto expected to remain profitable. FD remains the "cash machine," with future growth from innovation, though margins are expected to be stable. Bernstein views Swiggy as its top pick due to its Instamart performance and profitability path.
**Impact**: This news is likely to boost investor confidence in Swiggy and Zomato, potentially driving their stock prices towards the set targets. The detailed market analysis may also attract broader interest in the Indian tech and consumer sectors. Impact Rating: 8/10
**Heading: Difficult Terms and Their Meanings** **Brokerage**: A firm that helps investors buy and sell securities. **Initiated Coverage**: Began regularly publishing research and recommendations on a company. **Outperform**: A rating suggesting a stock will perform better than the market average. **Target Price (TP)**: Analyst's projection of a stock's future price. **Food Delivery (FD)**: Service of delivering meals from restaurants. **Quick Commerce (QC)**: Extremely fast delivery service (often within minutes). **GDP per capita**: Gross Domestic Product divided by the population, indicating economic output per person. **FY (Fiscal Year)**: A 12-month accounting period (India: April 1 - March 31). **Mom-and-pop stores**: Small, independently owned businesses. **Scale Effects**: Cost advantages due to a company's size. **Network Effects**: A product/service becomes more valuable as more people use it. **Profitability Glide Path**: A projected timeline for a company to become profitable. **Bourses**: Stock exchange. **Sensex**: A BSE index of 30 major Indian companies.
Brokerage Reports
3 ‘Buy’ recommendations by Motilal Oswal, with up to 28% upside potential
Brokerage Reports
Who Is Dr Aniruddha Malpani? IVF Specialist And Investor Alleges Zerodha 'Scam' Over Rs 5-Cr Withdrawal Issue
Brokerage Reports
Vedanta, BEL & more: Top stocks to buy on November 4 — Check list
Brokerage Reports
Stocks to buy: Raja Venkatraman's top picks for 4 November
Brokerage Reports
Ajanta Pharma offers growth potential amid US generic challenges: Nuvama
Brokerage Reports
Bernstein initiates coverage on Swiggy, Eternal with 'Outperform'; check TP
Consumer Products
Whirlpool India Q2 net profit falls 21% to ₹41 crore on lower revenue, margin pressure
Economy
Is India's tax system fueling the IPO rush? Zerodha's Nithin Kamath thinks so
Industrial Goods/Services
Ambuja Cements aims to lower costs, raise production by 2028
Consumer Products
Women cricketers see surge in endorsements, closing in the gender gap
Economy
Earning wrap today: From SBI, Suzlon Energy and Adani Enterprise to Indigo, key results announced on November 4
Banking/Finance
‘Builders’ luxury focus leads to supply crunch in affordable housing,’ D Lakshminarayanan MD of Sundaram Home Finance
Auto
Norton unveils its Resurgence strategy at EICMA in Italy; launches four all-new Manx and Atlas models
Auto
SUVs toast of nation, driving PV sales growth even post GST rate cut: Hyundai
Auto
Farm leads the way in M&M’s Q2 results, auto impacted by transition in GST
Auto
Tesla is set to hire ex-Lamborghini head to drive India sales
Auto
Mahindra in the driver’s seat as festive demand fuels 'double-digit' growth for FY26
Auto
Mahindra & Mahindra’s profit surges 15.86% in Q2 FY26
Healthcare/Biotech
Stock Crash: Blue Jet Healthcare shares tank 10% after revenue, profit fall in Q2
Healthcare/Biotech
Novo sharpens India focus with bigger bets on niche hospitals
Healthcare/Biotech
Dr Agarwal’s Healthcare targets 20% growth amid strong Q2 and rapid expansion
Healthcare/Biotech
Sun Pharma Q2 Preview: Revenue seen up 7%, profit may dip 2% on margin pressure